Grayscale pitched $HYPG to a16z, Goldman, Bloomberg, JPM, and Multicoin yesterday. Hyperliquid now has TradFi attention—institutional curiosity is real. Watch for capital flows if these names start positioning. Early signal that perps infrastructure is moving from crypto-native to Wall Street radar.
Blockstream's OP_CHECKSHRINCS introduces a dual-path signature scheme for Bitcoin transactions.
Path 1: Optimized for efficiency. Device maintains a signature counter to enable compact signatures, reducing on-chain footprint and transaction costs under normal operations.
Path 2: Failsafe mechanism. Counter-independent spending path remains permanently accessible. Higher transaction cost due to larger signature size, but guarantees fund access if hardware is lost, damaged, or replaced.
Recovery scenario: Seed phrase restoration bypasses counter state, defaulting to Path 2. Trade-off is clear—pay premium fees or lose access to capital.
Operational implication: Users optimize for Path 1 in standard conditions, Path 2 functions as insurance against device failure. No fund lockout risk, but economic penalty exists for recovery events.
Market selling off into earnings season. Valuation compression creating entry points—no bubble premium left in most names. $AI thesis intact, secular not cyclical. Noise around near-term concerns irrelevant to 3-5 year IRR. Risk/reward skewed positive if earnings hold up. Buyers' market forming.
$LLY deploying GLP-1 windfall into psychedelics M&A. Smart capital allocation if they're hedging on next-gen CNS pipeline. GLP-1 revenue stream gives them dry powder to diversify beyond obesity/diabetes. Watch for deal multiples and clinical stage of target—early-stage psych assets are high beta but could pay off if regulatory path clears. Bullish if they're not overpaying.